618 related articles for article (PubMed ID: 17519900)
1. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Kamba T; McDonald DM
Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of anticancer agents that target the VEGF pathway.
Chen HX; Cleck JN
Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Bose D; Meric-Bernstam F; Hofstetter W; Reardon DA; Flaherty KT; Ellis LM
Lancet Oncol; 2010 Apr; 11(4):373-82. PubMed ID: 20171141
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Girardi F; Franceschi E; Brandes AA
Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Snider KL; Maitland ML
Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
[TBL] [Abstract][Full Text] [Related]
7. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Ravaud A; Sire M
Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
[No Abstract] [Full Text] [Related]
8. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Herbst RS
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
[TBL] [Abstract][Full Text] [Related]
9. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
10. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
11. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
13. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
14. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud A
Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
16. Reversible cardiomyopathy associated with sunitinib and sorafenib.
Uraizee I; Cheng S; Moslehi J
N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
[No Abstract] [Full Text] [Related]
17. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
18. Renal toxicity of targeted therapies.
Kelly RJ; Billemont B; Rixe O
Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
[TBL] [Abstract][Full Text] [Related]
19. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Coriat R; Ropert S; Mir O; Billemont B; Chaussade S; Massault PP; Blanchet B; Vignaux O; Goldwasser F
Invest New Drugs; 2011 Oct; 29(5):1090-3. PubMed ID: 20524036
[TBL] [Abstract][Full Text] [Related]
20. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
